SUNNYVALE, Calif.--(BUSINESS WIRE)--Arrayit Corporation (OTCBB: ARYC) announced today that it has sold a third advanced microarray manufacturing system to the University of Texas Southwestern Medical Center at Dallas. The NanoPrint LM60 Microarrayer equipped with Arrayit’s Patented Microarray Manufacturing Technology (US Patent 6,101,946) is a computer-driven robotic microarray manufacturing system that enables the screening of 1.5 million lead therapeutic compounds per run, and the NanoPrint LM210 enables more than 5 million. UT Southwestern will use the NanoPrint LM60 to screen large libraries of potential therapeutic small molecules involved in cancer and heart disease. These small molecules have advantageous stability and biological activity, are suitable for drug delivery, and are easily manufactured in large, diverse libraries, making them attractive for therapeutic use. The use of Arrayit’s technology and UT Southwestern’s systematic approach has already led to the discovery of specific compounds known to be involved in cancer and cardiovascular disease.
